Research programme: nanobodies - Ablynx/Merck & Co

Latest Information Update: 26 Oct 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Ablynx
Class Proteins
Mechanism of Action Immunomodulators; Ion channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Cancer
No development reported Neurological disorders

Most Recent Events

12 Oct 2016 Ablynx and Merck announce a second extension of their collaboration agreement for development of ion channel nanobodies
16 Jul 2016 No recent reports of development identified for research development in Neurological-disorders in Belgium
03 Feb 2014 Early research in Cancer in Belgium (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.